Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 10/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2740980 | 0.90 | KDM4E (0.54) | ACLYKLK7KDM4EMEN1KMT2A | |
| SCHEMBL14160377 | 0.85 | ACLY (0.50) | ACLYPDK1PDK2PDK3PDK4 | |
| SCHEMBL7573034 | 0.76 | ACLY (0.53) | ACLYKDM4ESMN1; SMN2CMA1TSHR | |
| SCHEMBL2740996 | 0.75 | PTGES2 (0.56) | KDM4EMEN1KMT2ASMN1; SMN2PTK2B | |
| SCHEMBL6542555 | 0.75 | TSHR (0.56) | ACLYKDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL30955855 | 0.74 | CMA1 (0.46) | ACLYMEN1KMT2ASMN1; SMN2CMA1 | |
| SCHEMBL25734509 | 0.74 | CMA1 (0.46) | ACLYMEN1KMT2ASMN1; SMN2CMA1 | |
| SCHEMBL6541151 | 0.73 | MEN1 (0.53) | ACLYKDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL22315383 | 0.73 | ACLY (0.55) | ACLYKDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL1460210 | 0.72 | ALDH1A1 (0.54) | PDK1PDK2PDK3PDK4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088772-B2 | Sulfonamides and their use as a medicament | THE GENETICS COMPANY, INC. (CH) | 2012-01-03 | — | — | US | disclosed |
| US-8088772-B2 | Sulfonamides and their use as a medicament | THE GENETICS COMPANY, INC. (CH) | 2012-01-03 | — | — | US | disclosed |
| US-20100249135-A1 | SULFONAMIDES AND THEIR USE AS A MEDICAMENT | THE GENETICS COMPANY, INC. (CH) | 2010-09-30 | — | — | US | disclosed |
| US-20100249135-A1 | SULFONAMIDES AND THEIR USE AS A MEDICAMENT | THE GENETICS COMPANY, INC. (CH) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249135-A1 | SULFONAMIDES AND THEIR USE AS A MEDICAMENT | BCOR, CBR3, SULT1E1 | ACLY 2671/4885PDK1 3704/4885PDK2 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.